Connect with us

Business

Biohaven CEO says drug approval is ‘monumental’ for migraine patients – CNBC

“This is going to change the paradigm in which migraine is treated,” Biohaven Pharmaceutical CEO Vlad Coric said after Nurtec…

Published

on

Article feature image
ADVERTISEMENT

Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.
The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
America’s Biggest Sandwich Chain May Be Serving Fake Tuna, According to Lab Analysis | Eat This Not That – Eat This, Not That
Article feature image
Stock market’s most popular trade faces ‘perfect storm’ – Fox Business
Article feature image
Supply chain snafus could affect what’s available to you on Amazon Prime Day – CNBC